ICLE 2022 | Expanding the clinical applications of AvidCAR T-cells
Michael Traxlmayr, PhD, University of Natural Resources and Life Sciences, Vienna, Austria, discusses the advantages and potential applications of avidity-controlled chimeric antigen receptor (AvidCAR) T-cells, which have a lower antigen-binding affinity compared to typical CAR T-cells. The AvidCAR platform consequently enables regulation of CAR activity via dimerization with a small molecule inhibitor. Increased specificity also enables AvidCAR T-cells to only target cells positively expressing the two relevant antigens, avoiding the death of bystander cells. Dr Traxlmayr additionally highlights the need to find relevant antigen pairs for successful clinical translation. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
